Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ALDER BIOPHARMACEUTICALS INC (ALDR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/22/2019 8-K Quarterly results
09/16/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
05/24/2019 8-K Quarterly results
05/02/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Opinion of Cooley LLP",
"Opinion of Cooley LLP"
05/02/2019 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Reports First Quarter 2019 Financial and Operating Results - FDA sets eptinezumab PDUFA date of February 21, 2020; launch expected in first quarter of 2020 - - Acute study planned for potential eptinezumab label expansion -"
04/12/2019 8-K Quarterly results
03/28/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
03/28/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
03/05/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Registration Rights Agreement by and between Alder BioPharmaceuticals, Inc. and the buyers listed on the Schedule of Buyers thereto"
03/01/2019 8-K Quarterly results
02/25/2019 8-K Quarterly results
02/08/2019 8-K Quarterly results
01/17/2019 8-K Other Events
Docs: "FORM 8-K"
01/04/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Opinion of Cooley LLP",
"Distribution Agreement, by and between Alder BioPharmaceuticals, Inc. and J.P. Morgan Securities LLC"
12/11/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
11/05/2018 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Reports Third Quarter 2018 Financial and Operating Results - Biologics License Application submission on track for Q1 2019 - - Robust manufacturing package for BLA submission to include"
11/05/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
10/24/2018 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 23, 2018 Alder BioPharmaceuticals, Inc. Delaware 001-36431 90-0134860 11804 North Creek Parkway South Bothell, WA 98011 205-2900 Registrant's telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-comm..."
07/23/2018 8-K Other Events
06/11/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 4, 2018 Alder BioPharmaceuticals, Inc. Delaware 001-36431 90-0134860 11804 North Creek Parkway South Bothell, WA 98011 205-2900 Registrant's telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commence..."
05/25/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
05/08/2018 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results - 12-Month Data Presented at American Academy of Neurology Annual Meeting Demonstrated Eptinezumab Further Reduced Migraine Risk Following Third and Fourth Quarterly Infusions -"
04/26/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
04/16/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 16, 2018 Alder BioPharmaceuticals, Inc. Delaware 001-36431 90-0134860 11804 North Creek Parkway South Bothell, WA 98011 205-2900 Registrant's telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen..."
03/20/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 15, 2018 Alder BioPharmaceuticals, Inc. Delaware 001-36431 90-0134860 11804 North Creek Parkway South Bothell, WA 98011 205-2900 Registrant's telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen..."
02/23/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
02/13/2018 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ...
Docs: "Opinion of Cooley LLP",
"Opinion of Cooley LLP"
02/09/2018 8-K Asset disposition
Docs: "Opinion of Cooley LLP",
"Updated Risk Factors"
02/01/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Underwriting Agreement",
"Base Indenture, between the Company and U.S. Bank National Association, as Trustee",
"First Supplemental Indenture, between the Company and U.S. Bank National Association, as Trustee (including the form of 2.50% convertible senior notes due 2025)",
"Opinion of Cooley LLP",
"Statement Regarding Computation of Ratio of Earnings to Fixed Charges and Ratio of Earnings to Combined Fixed Charges and Preferred Stock Dividends"
01/19/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "FORM 8-K",
"Certificate of Designation of Preferences, Rights and Limitations of Class A-1 Convertible Preferred Stock of Alder BioPharmaceuticals",
"Registration Rights Agreement by and between Alder BioPharmaceuticals, Inc. and the buyers listed on the Schedule of Buyers thereto"
01/11/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Preferred Stock Purchase Agreement by and among Alder BioPharmaceuticals, Inc. and the Buyers set forth therein",
"Alder Announces $250 Million Committed Equity Financing"
01/08/2018 8-K Quarterly results
11/07/2017 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Announces Third Quarter 2017 Financial and Operating Results – PROMISE 2 pivotal trial completed enrollment and top-line data on track for 1H18 –"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy